{"name":"Instituto Grifols, S.A.","slug":"instituto-grifols-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Fibrin Sealant Grifols","genericName":"Fibrin Sealant Grifols","slug":"fibrin-sealant-grifols","indication":"Hemostasis and tissue sealing during surgical procedures","status":"phase_3"},{"name":"Human thrombin","genericName":"Human thrombin","slug":"human-thrombin","indication":"Other","status":"marketed"},{"name":"Prolastin","genericName":"Prolastin","slug":"prolastin","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Flebogamma 5% DIF","genericName":"Flebogamma 5% DIF","slug":"flebogamma-5-dif","indication":"Primary immunodeficiency disorders","status":"marketed"},{"name":"IGIV3I Grifols","genericName":"IGIV3I Grifols","slug":"igiv3i-grifols","indication":"Primary immunodeficiency disorders","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bovine thrombin","genericName":"Bovine thrombin","slug":"bovine-thrombin","indication":"Hemostasis in surgical procedures","status":"marketed"}]}],"pipeline":[{"name":"Fibrin Sealant Grifols","genericName":"Fibrin Sealant Grifols","slug":"fibrin-sealant-grifols","phase":"phase_3","mechanism":"Fibrin Sealant Grifols is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgical procedures.","indications":["Hemostasis and tissue sealing during surgical procedures","Reduction of postoperative bleeding in general, cardiac, and vascular surgery"],"catalyst":""},{"name":"Human thrombin","genericName":"Human thrombin","slug":"human-thrombin","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Bovine thrombin","genericName":"Bovine thrombin","slug":"bovine-thrombin","phase":"marketed","mechanism":"Bovine thrombin is a serine protease that directly converts fibrinogen to fibrin, promoting blood clotting and hemostasis.","indications":["Hemostasis in surgical procedures","Control of bleeding in patients with coagulation disorders","Topical hemostasis in wound management"],"catalyst":""},{"name":"Flebogamma 5% DIF","genericName":"Flebogamma 5% DIF","slug":"flebogamma-5-dif","phase":"marketed","mechanism":"Flebogamma 5% DIF is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency in hematologic malignancies","Idiopathic thrombocytopenic purpura (ITP)","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Multifocal motor neuropathy (MMN)"],"catalyst":""},{"name":"IGIV3I Grifols","genericName":"IGIV3I Grifols","slug":"igiv3i-grifols","phase":"phase_3","mechanism":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions","Autoimmune and inflammatory disorders"],"catalyst":""},{"name":"Prolastin","genericName":"Prolastin","slug":"prolastin","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQc3JFcTRPaDdDVlF6bTVrTXp3OTZUdHdhRVB2M05CeWZBVy1GZUl0QmVHT1Y5cnNaZEl5dFpaMHhqbTEzVWtPSTFKVEJyWHRXZ3E3S3dESlVSclNyYmtTMWhJZ1V4VjRJY3VicXU1YXhXYk1CNGhZTTF2ZElUNDM1QzJjU2htMy00RmJ6M0NDbWRVb3VBY0E?oc=5","date":"2025-12-08","type":"pipeline","source":"Seeking Alpha","summary":"Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha","headline":"Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUzllU1lTVlM2UDdmN2lWNzlsdmJBM3NYQ2ppdmFuLUxZc19hS3RBZmFKYXN2aEpuTHE1S0VIdmdUVGgtUG90dHlEX1VYVTgxZ08wWkw3U3I4MDA0UWVka3pya0pyZVJqS0hGd2hncDM3dEZsdkRreDRJRTFYTkR4b0t0d0llM3hPNTZCY2llR3A3dF9Db2l5Q2pLVk8tUExfcFhyX2lheWZDMWRkUXlmOHVmY2xiUXg3RU9GMQ?oc=5","date":"2025-10-09","type":"pipeline","source":"Reuters","summary":"Spanish court summons Gotham City founder in Grifols share price probe - Reuters","headline":"Spanish court summons Gotham City founder in Grifols share price probe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSWpUZF82OUF5eHpsSm9LU3ZrS3l6TW5lX3hqR0otTDRIWDhpNmhKTVBQMkg0TkRxYmkyTldlbXRxZ1pQTHpSa0NGbFJMQzJMLWstS1EyQ0k2SEFnbHVXRlY5bUpqc2JwbDRzd1RIZXJ1U0wtb1AyQUhhdklEb3VLN1E3RTVocmlFRldrVnFKbV91c0RJNFVjS3JGR2d0aVN3NmlOYU9aajE?oc=5","date":"2025-08-12","type":"pipeline","source":"The Globe and Mail","summary":"Spanish drugmaker using Canadian-donated blood plasma for products sold abroad - The Globe and Mail","headline":"Spanish drugmaker using Canadian-donated blood plasma for products sold abroad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVV9BcVNCd2FlaDVpMEhqYkNfOFY4T0pVb0lMbi1ubUNONXU4eDNPZUdwOW1KQTJQT0V3aG14RnR1QnJzUlhhUDRVWklTZHpJRTZMR29LNjhmb0tCdlVyOFlOQ21iSm1GVXowMldtMFB1QjJQSlVEdnJTdkNQZHFhV2N5djdpczlLOU5NM0Ffd29TVmlOdl9tV2l1WGJsTmZmZEFYcVRtOFdENzJveHF0UWtZdDcxekdLcDJOemVYVTZxNHZYamlMVTBtdVBIR21aMXc4?oc=5","date":"2025-04-02","type":"pipeline","source":"Reuters","summary":"Spanish pharma company Grifols' shares up on Brookfield talk - Reuters","headline":"Spanish pharma company Grifols' shares up on Brookfield talk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPQVlBWUxyQ1k3N0l2TWZhbFdGX1hVUEQ4T2c0OTllVm9tRExNVElhaDcwRVVoZDFoWkg4bkM2NmxBWUZSVHVhZkZQazFOTkpPS2tWT180MlkzZ0V1Sk14WUJkTU1qZktJMDEyUXVnY1ZNXzN4ZThPbXJWTUtfSU5iOElXTnJhTS15elVZLVduOEl5a0Q3dWlXTjBjSjVYNkl1NDJlOXVtVVlEdU5heE1GaXFwOA?oc=5","date":"2024-11-27","type":"pipeline","source":"The Globe and Mail","summary":"Brookfield abandons plan for €6.45-billion takeover of drug maker Grifols - The Globe and Mail","headline":"Brookfield abandons plan for €6.45-billion takeover of drug maker Grifols","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxObzQ3MFpWV3pFZzFORDdQbDJNTG5fZHZWMGF5SkxiVXBQaVpHNXdNSVlzX0Z1ZGJlU3FrNWg0WUl0VUEwa0lIUGVoMlBvZV9zTWVnUGIxYXR6ZkxXc0UyYXVCR3FDRl9INTMtMVZTbWpZd0ZHRUNWR1VRLWJjSVp2NXZNeE1zVXBlWER0TFlrOTkxOFE0TWNCWFhYb1VwRmdGbWlSY29oRmtuTUR1NEFOejdNTGVuOTd1?oc=5","date":"2024-07-08","type":"pipeline","source":"The Globe and Mail","summary":"Brookfield teams up with Spain’s Grifols family to explore a bid for Spanish drug maker - The Globe and Mail","headline":"Brookfield teams up with Spain’s Grifols family to explore a bid for Spanish drug maker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOLUE0QkRTNmtNMThLV2NWVHA3YWNQeTdESmtiUWpUUlRQYi1UVU5SQ1VRX3hwQU5ueEUwWnFKT20tcHVuRWZKSC1wWF9wWURTR2dvZjVIWE42RE56R1liM0llUFZBU0hWSkxVVzA3RWZ3bDJoMEZDUHhNUHM5YUNLSGM0dUJ1WjNOMFc4YTVQSGFHNUpyVUREbXJXaVg2ZmExMGF6SFBTRzUtQ2RiUmMxc1J3MFVQMTdvSDNrdTFuNEgwdFhIdGZxXw?oc=5","date":"2023-02-21","type":"pipeline","source":"Reuters","summary":"Executive chairman of Spanish pharma company Grifols resigns - Reuters","headline":"Executive chairman of Spanish pharma company Grifols resigns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPcFc1aG5WRWZRamFsUnkwXzh2S1pNT01WcENNTnE5YUtBbVVqNzNHUkkxZjIxVTZ0VlRVdTFIQ1VJNG5Gc2tydExwQ0dTZWRPZHhOU084NTJ4eHZaN2lZUGhXdlJLLXh6TDdONWJWMWRfdEU4eXpqYW5IQTB0bDJoeEdZbWpBWEw0SzhGTExTODJEa3VRWGI1VUIzMV93OFhhNG5TdFlhU3k0eDdjQS1DWk1WRVNUYTg?oc=5","date":"2023-02-16","type":"pipeline","source":"Reuters","summary":"Shares at Spain's Grifols rise on cost-cutting plan - Reuters","headline":"Shares at Spain's Grifols rise on cost-cutting plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNOTV5VWk1QnkwcXAtQkhURWRuR2JmU2hiZXJvSk1ydXVxb25ma3Q0bkpqYjhJdmxCVElMVERjRWdXc09nYWQ1dklYdDh1X25LaTRFcnVxNzhXZTA4djBCaWlkQVVySXpXYmlPYmU2WnFfSEpnV1NVTE1rSkJiQUJTN0owR0paZ2JQQnZoaTZmTXF5aG1wLW53c2FTM2UyTThMNGFLUzE3TENYajhyRXp6S0xrQ1lVSXphMXJNdE0tbHMwb3VrVEhr?oc=5","date":"2022-10-19","type":"pipeline","source":"Fierce Pharma","summary":"Grifols christens capacity-tripling albumin plant, pledging 200 new jobs in latest plasma push - Fierce Pharma","headline":"Grifols christens capacity-tripling albumin plant, pledging 200 new jobs in latest plasma push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPV0hZaUFfUHFoWlRickl1UVpUWXptdFVPWEU4TUxrdkhraklORWR4azJLWXRMOGlqR1B2bk9GVWRqd1BBbXB1aTIyNmw1V3Yza3I3YXZKb1NiT1YyVjZCVDY1OGVZVkpHV0RrR3lVeUNBcGphT2VROHhGZEFfSlpNZ3h3Zm1sQmppNTBVUlVDMEVSb19TUnc?oc=5","date":"2019-11-08","type":"pipeline","source":"Fortune Business Insights","summary":"Plasma Fractionation Market Size, Share | Global Report [2034] - Fortune Business Insights","headline":"Plasma Fractionation Market Size, Share | Global Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQdTVRZW9kT2dtQl9Tdk94MEhPaDFZZkpOWVM4UlJheVhXUzBXWDFFSWQ2cjhpaW1faTgzUmF1eS1VdkdCX3BNMVQ4U05Hb1diYU02ankxaWluOFRsWnFXeDVHYzg2VFBZcC15ampnVjF1M19YLUNhYldmaTBjd3hjRTVzT0RUeVFaanBUSE03d2pMdw?oc=5","date":"2019-07-27","type":"regulatory","source":"fda.gov.ph","summary":"Intensified Campaign Against Counterfeit Pharmaceutical Products - fda.gov.ph","headline":"Intensified Campaign Against Counterfeit Pharmaceutical Products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPc2pGdmxSVHdaeUNmLV9RTGRTLW55aVY0ODJRWFU3TFQ4amFuSEtUUGE5ZzQyQ2ViZTVaYmQ4eXBQUnZBaW1yb1dITk1HYVlUX1lXbXplX1JHd2F1R205UXNGSXRwSHJKVVV0TWdqT0Q1V2I0QlhXSFZsdXY1c0J4Nk5jNWZrUQ?oc=5","date":"2010-12-06","type":"pipeline","source":"Business Insider","summary":"Wikileaks Unveils Over 300 Foreign Sites That Are Critical To U.S. National Interests - Business Insider","headline":"Wikileaks Unveils Over 300 Foreign Sites That Are Critical To U.S. National Interests","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":2,"marketed":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}